Anebulo Pharmaceuticals, Inc.

NASDAQ•ANEB

執行長: Dr. Joseph F. Lawler M.D., Ph.D.

板塊: Healthcare

行業: Biotechnology

上市日期: 2021-05-07

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.

聯絡資訊

1017 Ranch Road 620 South, Suite 107, Lakeway, TX, 78734, United States

512-598-0931

www.anebulo.com

市值

$16.31M

本益比 (TTM)

-2.1

17.8

股息率

52周最高

$3.42

52周最低

$0.30

52周範圍

排名56Top 81.7%

2.5

F-Score

改良版 Piotroski 分析

基於 6 年期基本面

疲弱 • 2.5 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2020-2025

財務儀表板

Q2 2026 數據

營業收入

$0.00+0.00%

近4季度走勢

每股收益

-$0.05+0.00%

近4季度走勢

自由現金流

-$1.31M+0.00%

近4季度走勢

2026 Q2 財報亮點

核心亮點

Six Month Net Loss Reduced Six month net loss decreased to $(4.158M) USD, reflecting $506K improvement against prior period results.

R&D Spending Decreased Six month R&D expenses fell $561K USD to $1.975M, due to lower contract manufacturing activities.

Cash Position Maintained Cash and equivalents stood at $9.042M USD as of December 31, 2025, following operating cash usage.

Financing Provided Cash Inflow Financing activities provided $15.0M USD cash inflow, supporting operations before the reporting period end date.

關注風險

Future Funding Dependency Expect continued operating losses; cash runway estimated for 12 months requiring future capital raises.

Clinical Trial Uncertainty Success hinges on favorable clinical trial results and obtaining necessary regulatory approvals for product candidates.

Going Private Liquidity Risk Plan to delist from Nasdaq; reduced public information availability may increase stock illiquidity and volatility.

Equity Dilution Risk Future equity financing or Loan Agreement stock issuance will cause substantial dilution to existing common stockholders.

未來展望

Prioritizing Pediatric IV Formulation Prioritizing intravenous formulation development for pediatric indication, seeking faster regulatory pathway for emergency treatment.

IV Study Currently Ongoing Initiated ongoing single ascending dose study for IV selonabant in healthy adults during third quarter 2025.

Government Operations Disruption Risk Future government shutdowns pose risk to timely regulatory reviews, grant disbursements, and clinical trial oversight.

G&A Expenses Expected Decline General administrative expenses expected to decrease following completion of planned deregistration from SEC reporting.

同行對比

營業收入 (TTM)

MGNX

$126.00M

-10.8%

ZNTL

$26.87M

-33.8%

SRZN

$3.60M

-64.0%

毛利率 (最新季度)

SRZN

100.0%

+0.0pp

MGNX

81.6%

+19.9pp

ANEB

0.0%

+0.0pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
SRZN	$245.06M	-2.8	-4404.2%	7.5%
ZNTL	$157.87M	-1.1	-51.5%	11.2%
MGNX	$135.37M	-1.8	-98.3%	13.7%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

N/M

營業收入波動較大

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

現金流需要關注

深度研究

下次財報:2026年5月11日

每股收益:-

營業收入:-

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料